Paclitaxel for Recurrent Ovarian Cancer
Links shared publicly online about this topic
Predicting Cellular Response To Paclitaxel In Epithelial Ovarian Cancer
medicalnewstoday.com — “New research findings by UCD scientists published online today in the Journal of Pathology may help clinicians predict how patients with high grade, serous, epithelial ovarian cancer will respond” View full resource at medicalnewstoday.com
Most Recently Shared on November 12, 2011 at 8:05 am By:
MNT Ovarian Cancer Health News
Predicting Cellular Response To Paclitaxel In Epithelial Ovarian Cancer http://t.co/X7z0k7d9 #ovariancancer
Predicting cellular response to paclitaxel in epithelial ovarian cancer
medicalxpress.com — “(Medical Xpress) -- New research findings by UCD scientists published online in the Journal of Pathology may help clinicians predict how patients with high grade, serous, epithelial ovarian cancer will respond to paclitaxel chemotherapy (Taxol).” View full resource at medicalxpress.com
Most Recently Shared on November 16, 2011 at 4:09 pm By:
Predicting cellular response to paclitaxel in epithelial ovarian cancer: (Medical Xpress) -- New research findin... http://t.co/Wd8cS7gk
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - ONA
oncologynurseadvisor.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 7, 2010 at 8:20 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer http://goo.gl/fb/vAkMj
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - MPR
empr.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at empr.com
Most Recently Shared on June 7, 2010 at 8:14 pm By:
MPR News: Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer: Amgen announced that AMG 386, combin... http://bit.ly/cBbIUj
GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer
news-medical.net — “Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.” View full resource at news-medical.net
Most Recently Shared on November 1, 2010 at 4:49 pm By:
Lung Cancer News: GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer: Syn... http://bit.ly/91GDOX
First Recurrent Gene Fusion Identified In Ovarian Cancer
medicalnewstoday.com — “Researchers studying ovarian cancer have discovered that, in a substantial fraction of ovarian tumors, a gene closely related to the estrogen receptor is broken and fused to an adjacent gene by a” View full resource at medicalnewstoday.com
Most Recently Shared on September 22, 2011 at 7:05 am By:
MNT Ovarian Cancer Health News
First Recurrent Gene Fusion Identified In Ovarian Cancer http://mnt.to/3ZMY #ovariancancer
Oncology Article | Carboplatin Ovarian Neoplasms Paclitaxel
mdlinx.com — “Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer” View full resource at mdlinx.com
Most Recently Shared on January 31, 2011 at 6:17 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-r... http://bit.ly/eDTbxA #oncology
Oncology Article | Carboplatin Ovarian Neoplasms Paclitaxel
mdlinx.com — “Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/ refractory epithelial ovarian cancer” View full resource at mdlinx.com
Most Recently Shared on July 13, 2011 at 7:49 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery o... http://bit.ly/qLdG64 #oncology
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer - Drugs.com MedNews
drugs.com — “THOUSAND OAKS, Calif., Amgen (Nasdaq AMGN) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial invo” View full resource at drugs.com
Most Recently Shared on October 11, 2010 at 11:06 pm By:
Drugs and Devices OW OW Health
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer: THOU... http://bit.ly/b2PL9F #drug
ScienceDirect - Gynecologic Oncology : A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group
sciencedirect.com — “ScienceDirect - Gynecologic Oncology : A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study” View full resource at sciencedirect.com
Most Recently Shared on May 31, 2011 at 4:15 am By:
Paul Cacciatore Patient Advocate
GOG ph. 2 study: M.D. Anderson finds wkly nab-paclitaxel has clinical efficacy in resistant/refractory ovarian cancer. http://dld.bz/abFcJ
Ovarian cancer vaccine: Can it prevent recurrence? - MayoClinic.com
mayoclinic.com — “Research continues to evaluate the role of an ovarian cancer vaccine to prevent recurrence.” View full resource at mayoclinic.com
Most Recently Shared on March 24, 2012 at 2:20 am By:
Julie Bohlen Health Executive and Active Health Library
Ovarian cancer vaccine: Can it prevent recurrence?: Research continues to evaluate the role of an ovarian cancer... http://t.co/fbwU0zDZ
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer
medicalnewstoday.com — “Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2011 at 9:07 am By:
MNT Ovarian Cancer Health News
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer http://t.co/7OgdD8rC #ovariancancer
For The Treatment Of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin
medicalnewstoday.com — “Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard o” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2010 at 3:37 pm By:
For The Treatment Of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin De.. http://dld.bz/AcP7
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer
onclive.com — “Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.” View full resource at onclive.com
Most Recently Shared on July 27, 2011 at 7:45 pm By:
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer http://t.co/gLOIrDB
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability - ONA
oncologynurseadvisor.com — “The combination of oxaliplatin and doxorubicin showed promising efficacy in either platinum-sensitive or platinum-resistant recurrent ovarian cancer, as reported by Ilya Pokateav, MD, from the Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 5:23 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability http://goo.gl/fb/ldXlW
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MNT Ovarian Cancer
The latest ovarian cancer news published daily. Articles from research centers, universities and prestigious journals.
-
Ovarian Cancer OW
Organizing ovarian cancer resources shared by health experts, advocates, and organizations into WisdomCards.
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
Advertisement
